Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL oktober 28, 2022
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL september 30, 2022
General Nieuws Oxurion To Participate in Upcoming Scientific and Investor Conferences EN september 12, 2022
General Nieuws Regulated Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding EN NL september 2, 2022
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL augustus 26, 2022
General Nieuws Oxurion To Present at Upcoming Scientific and Investor Conferences EN augustus 24, 2022
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL juli 29, 2022
General Nieuws Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences EN juli 11, 2022
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds EN NL juni 30, 2022
General Nieuws Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting EN juni 13, 2022
General Nieuws Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting EN juni 3, 2022
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL mei 31, 2022
General Nieuws Regulated Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022 EN NL mei 25, 2022
General Nieuws Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022 EN mei 24, 2022
General Nieuws Regulated Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) EN NL mei 9, 2022
General Nieuws Regulated Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022 EN NL mei 6, 2022
